{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:28:27Z","timestamp":1793870907732,"version":"4.6.1"},"reference-count":74,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016304","name":"Medtronic plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016304","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Catheter-based radiofrequency renal denervation (RF RDN) has recently been approved for clinical use in the European Society of Hypertension guidelines and by the US Food and Drug Administration. This study evaluated the lifetime cost-effectiveness of RF RDN using contemporary evidence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>A decision\u2013analytic model based on multivariate risk equations projected clinical events, quality-adjusted life years (QALYs), and costs. The model consisted of seven health states: hypertension alone, myocardial infarction (MI), other symptomatic coronary artery disease, stroke, heart failure (HF), end-stage renal disease, and death. Risk reduction associated with changes in office systolic blood pressure (oSBP) was estimated based on a published meta-regression of hypertension trials. The base case effect size of \u22124.9\u00a0mmHg oSBP (observed vs. sham control) was taken from the SPYRAL HTN-ON MED trial of 337 patients. Costs were based on National Health Service England data. The incremental cost-effectiveness ratio (ICER) was evaluated against the UK National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold of \u00a320\u00a0000\u201330\u00a0000 per QALY gained. Extensive scenario and sensitivity analyses were conducted, including the ON-MED subgroup on three medications and pooled effect sizes. RF RDN resulted in a relative risk reduction in clinical events over 10 years (0.80 for stroke, 0.88 for MI, 0.72 for HF), with an increase in health benefit over a patient's lifetime, adding 0.35 QALYs at a cost of \u00a34763, giving an ICER of \u00a313\u00a0482 per QALY gained. Findings were robust across tested scenarios.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Catheter-based radiofrequency RDN can be a cost-effective strategy for uncontrolled hypertension in the UK, with an ICER substantially below the NICE cost-effectiveness threshold.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjqcco\/qcae001","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T07:05:53Z","timestamp":1704870353000},"page":"698-708","source":"Crossref","is-referenced-by-count":25,"title":["Cost-effectiveness of catheter-based radiofrequency renal denervation for the treatment of uncontrolled hypertension: an analysis for the UK based on recent clinical evidence"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9085-8881","authenticated-orcid":false,"given":"Andrew S P","family":"Sharp","sequence":"first","affiliation":[{"name":"Department of Cardiology, University Hospital of Wales and Cardiff University , Cardiff, CF14 4XW ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khoa N","family":"Cao","sequence":"additional","affiliation":[{"name":"Wing Tech Inc., Menlo Park , CA 94025 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray D","family":"Esler","sequence":"additional","affiliation":[{"name":"Human Neurotransmitters Laboratory, Baker IDI Heart and Diabetes Institute , Melbourne, VIC 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E","family":"Kandzari","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, Piedmont Heart Institute , Atlanta, GA 30309 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin D","family":"Lobo","sequence":"additional","affiliation":[{"name":"Bart\u2019s Blood Pressure Clinic, Bart\u2019s Health NHS Trust , London E1 2ES ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2356-5883","authenticated-orcid":false,"given":"Roland E","family":"Schmieder","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, University Hospital Erlangen , 91054 Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5078-1939","authenticated-orcid":false,"given":"Jan B","family":"Pietzsch","sequence":"additional","affiliation":[{"name":"Wing Tech Inc., Menlo Park , CA 94025 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"key":"2024121909364697200_bib1","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"2024121909364697200_bib2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2016.19043","article-title":"Global burden of hypertension and systolic blood pressure of at least 110 to 115\u00a0mm Hg, 1990\u20132015","volume":"317","author":"Forouzanfar","year":"2017","journal-title":"J Am Med Assoc"},{"key":"2024121909364697200_bib3","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1097\/HJH.0000000000002933","article-title":"European Society of Hypertension position paper on renal denervation 2021","volume":"39","author":"Schmieder","year":"2021","journal-title":"J Hypertens"},{"key":"2024121909364697200_bib4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4244\/EIJV11I1A18","article-title":"Symplicity multi-electrode radiofrequency renal denervation system feasibility study","volume":"11","author":"Whitbourn","year":"2015","journal-title":"EuroIntervention"},{"key":"2024121909364697200_bib5","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","article-title":"Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial","volume":"395","author":"B\u00f6hm","year":"2020","journal-title":"Lancet North Am Ed"},{"key":"2024121909364697200_bib6","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.jacc.2023.08.045","article-title":"Safety and efficacy of renal denervation in the presence of antihypertensive medications: SPYRAL HTN-ON MED","volume":"82","author":"Kandzari","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2024121909364697200_bib7","volume-title":"SPYRAL HTN-ON MED trial results presentation at: AHA Annual Meeting","author":"Kandzari","year":"2022"},{"key":"2024121909364697200_bib8","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1093\/eurheartj\/ehz118","article-title":"Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry","volume":"40","author":"Mahfoud","year":"2019","journal-title":"Eur Heart J"},{"key":"2024121909364697200_bib9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1161\/HYPERTENSIONAHA.122.20853","article-title":"Catheter-based renal denervation: 9-year follow-up data on safety and blood pressure reduction in patients with resistant hypertension","volume":"80","author":"Sesa-Ashton","year":"2023","journal-title":"Hypertension"},{"key":"2024121909364697200_bib10","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1136\/heartjnl-2019-315098","article-title":"Joint UK societies\u2019 2019 consensus statement on renal denervation","volume":"105","author":"Lobo","year":"2019","journal-title":"Heart"},{"key":"2024121909364697200_bib11","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/eurheartj\/ehad054","article-title":"Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)","volume":"44","author":"Barbato","year":"2023","journal-title":"Eur Heart J"},{"key":"2024121909364697200_bib12","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"2024121909364697200_bib13","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s40258-014-0116-7","article-title":"Cost effectiveness of renal denervation therapy for the treatment of resistant hypertension in the UK","volume":"12","author":"Gladwell","year":"2014","journal-title":"Appl Health Econ Health Policy"},{"key":"2024121909364697200_bib14","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.jacc.2012.07.029","article-title":"Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension","volume":"60","author":"Geisler","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2024121909364697200_bib15","volume-title":"The Guidelines Manual","author":"National Institute for Health and Clinical Excellence","year":"2012"},{"key":"2024121909364697200_bib16","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1017\/S0266462321001732","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"38","author":"Husereau","year":"2022","journal-title":"Int J Technol Assess Health Care"},{"key":"2024121909364697200_bib17","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0002-8703(00)90236-9","article-title":"Primary and subsequent coronary risk appraisal: new results from the Framingham study","volume":"139","author":"D'Agostino","year":"2000","journal-title":"Am Heart J"},{"key":"2024121909364697200_bib18","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1161\/CIRCULATIONAHA.108.784215","article-title":"Long-term trends in the incidence of heart failure after myocardial infarction","volume":"118","author":"Velagaleti","year":"2008","journal-title":"Circulation"},{"key":"2024121909364697200_bib19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1161\/01.STR.25.1.40","article-title":"Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study","volume":"25","author":"D'Agostino","year":"1994","journal-title":"Stroke"},{"key":"2024121909364697200_bib20","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/ije\/31.6.1253","article-title":"Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular M\u00fcnster Study (PROCAM) using neural networks","volume":"31","author":"Voss","year":"2002","journal-title":"Int J Epidemiol"},{"key":"2024121909364697200_bib21","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1161\/STROKEAHA.107.510362","article-title":"Variables associated with 7-day, 30-day, and 1-year fatality after ischemic stroke","volume":"39","author":"Saposnik","year":"2008","journal-title":"Stroke"},{"key":"2024121909364697200_bib22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jstrokecerebrovasdis.2005.06.002","article-title":"Sex differences in stroke survival: 10-year follow-up of the Copenhagen stroke study cohort","volume":"14","author":"Andersen","year":"2005","journal-title":"J Stroke Cerebrovasc Diseases"},{"key":"2024121909364697200_bib23","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/01.STR.22.3.312","article-title":"Probability of stroke: a risk profile from the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"2024121909364697200_bib24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/0003-4819-141-2-200407200-00007","article-title":"The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency","volume":"141","author":"Hsu","year":"2004","journal-title":"Ann Intern Med"},{"key":"2024121909364697200_bib25","doi-asserted-by":"crossref","first-page":"e1003048","DOI":"10.1371\/journal.pmed.1003048","article-title":"Long-term trends in death and dependence after ischaemic strokes: a retrospective cohort study using the South London Stroke Register (SLSR)","volume":"17","author":"Wafa","year":"2020","journal-title":"PLoS Med"},{"key":"2024121909364697200_bib26","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2468-2667(17)30032-4","article-title":"Acute myocardial infarction hospital admissions and deaths in England: a national follow-back and follow-forward record-linkage study","volume":"2","author":"Asaria","year":"2017","journal-title":"Lancet Public Health"},{"key":"2024121909364697200_bib27","first-page":"532","article-title":"Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010","volume":"5","author":"Smolina","year":"2012","journal-title":"Circ: Cardiovasc Qual Outcomes"},{"key":"2024121909364697200_bib28","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","article-title":"Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1\u00b7 25 million people","volume":"383","author":"Rapsomaniki","year":"2014","journal-title":"Lancet North Am Ed"},{"key":"2024121909364697200_bib29","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1136\/bmj.b3058","article-title":"Five year prognosis in patients with angina identified in primary care: incident cohort study","volume":"339","author":"Buckley","year":"2009","journal-title":"Br Med J"},{"key":"2024121909364697200_bib30","first-page":"691","article-title":"Exercise-based rehabilitation for heart failure: cochrane systematic review, meta-analysis, and trial sequential analysis","volume":"7","author":"Taylor","year":"2019","journal-title":"JACC: Heart Fail"},{"key":"2024121909364697200_bib31","author":"UK Renal Registry","year":"2022"},{"key":"2024121909364697200_bib32","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/HJH.0000000000000378","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials","volume":"32","author":"Thomopoulos","year":"2014","journal-title":"J Hypertens"},{"key":"2024121909364697200_bib33","doi-asserted-by":"crossref","DOI":"10.1161\/HYPERTENSIONAHA.123.22251","article-title":"Impact of Antihypertensive Medication Changes after Renal Denervation among Different Patient Groups: SPYRAL HTN-ON MED","author":"Townsend","year":"2024","journal-title":"Hypertension"},{"key":"2024121909364697200_bib34","article-title":"Systematic Review of Renal Denervation for Uncontrolled Hypertension","author":"Marshall","year":"2022"},{"key":"2024121909364697200_bib35","article-title":"Cochrane handbook for systematic reviews of interventions (Version 6.3)","author":"Higgins","year":"2022","journal-title":"Cochrane"},{"key":"2024121909364697200_bib36","article-title":"Undertaking systematic reviews of research on effectiveness: CRD's guidance for carrying out or commissioning reviews","author":"Khan","year":"2001"},{"key":"2024121909364697200_bib37","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1016\/j.jacc.2020.04.036","article-title":"Renal denervation in high-risk patients with hypertension","volume":"75","author":"Mahfoud","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2024121909364697200_bib38","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jacc.2022.11.038","article-title":"10-Year outcomes of catheter-based renal denervation in patients with resistant hypertension","volume":"81","author":"Kulenthiran","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2024121909364697200_bib39","doi-asserted-by":"crossref","first-page":"1210801","DOI":"10.3389\/fcvm.2023.1210801","article-title":"Safety and efficacy of renal sympathetic denervation: a 9-year long-term follow-up of 24-hour ambulatory blood pressure measurements","volume":"10","author":"Vogt","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2024121909364697200_bib40","volume-title":"Inflation and price indices: Office for National Statistics","author":"Office for National Statistics (ONS)","year":"2022"},{"key":"2024121909364697200_bib41","article-title":"UK population norms for EQ-5D","author":"Kind","year":"1999"},{"key":"2024121909364697200_bib42","author":"Office for National Statistics (ONS)","year":"2021"},{"key":"2024121909364697200_bib43","author":"National Institute for Health and Care Excellence (NICE)","year":"2019"},{"key":"2024121909364697200_bib44","volume-title":"Sentinel Stroke National Audit Programme: cost and cost-effectiveness analysis","author":"National Guideline Centre & SSNAP","year":"2016"},{"key":"2024121909364697200_bib45","doi-asserted-by":"crossref","first-page":"e011805","DOI":"10.1136\/bmjopen-2016-011805","article-title":"Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK","volume":"6","author":"Danese","year":"2016","journal-title":"BMJ Open"},{"key":"2024121909364697200_bib46","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/ndt\/gfv224","article-title":"Understanding cost of care for patients on renal replacement therapy: looking beyond fixed tariffs","volume":"30","author":"Li","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2024121909364697200_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11140","article-title":"A systematic review and economic evaluation of statins for the prevention of coronary events","volume":"11","author":"Ward","year":"2007","journal-title":"Health Technol Assess"},{"key":"2024121909364697200_bib48","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3111\/13696998.2014.978453","article-title":"Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in the Netherlands","volume":"18","author":"Henry","year":"2015","journal-title":"J Med Econ"},{"key":"2024121909364697200_bib49","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/eurheartj\/ehr504","article-title":"The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study","volume":"34","author":"Comin-Colet","year":"2013","journal-title":"Eur Heart J"},{"key":"2024121909364697200_bib50","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1111\/j.1523-1755.2005.00752.x","article-title":"Health-related quality of life and estimates of utility in chronic kidney disease","volume":"68","author":"Gorodetskaya","year":"2005","journal-title":"Kidney Int"},{"key":"2024121909364697200_bib51","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet North Am Ed"},{"key":"2024121909364697200_bib52","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.HYP.0000236119.96301.f2","article-title":"The Valsartan antihypertensive long-term use evaluation (VALUE) trial","volume":"48","author":"Julius","year":"2006","journal-title":"Hypertension"},{"key":"2024121909364697200_bib53","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med"},{"key":"2024121909364697200_bib54","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Ontarget Investigators","year":"2008","journal-title":"New Engl J Med"},{"key":"2024121909364697200_bib55","first-page":"1174","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial","volume":"372","author":"Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease Investigators","year":"2008","journal-title":"Lancet North Am Ed"},{"key":"2024121909364697200_bib56","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study investigators","volume":"355","author":"Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","journal-title":"Lancet"},{"key":"2024121909364697200_bib57","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"key":"2024121909364697200_bib58","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomised trial of intensive versus standard blood-pressure control","volume":"373","author":"SPRINT Research Group","year":"2015","journal-title":"N Engl J Med"},{"key":"2024121909364697200_bib59","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","article-title":"Trial of intensive blood-pressure control in older patients with hypertension","volume":"385","author":"Zhang","year":"2021","journal-title":"N Engl J Med"},{"key":"2024121909364697200_bib60","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.gheart.2016.10.024","article-title":"The global burden of disease study and the preventable burden of NCD","volume":"11","author":"Benziger","year":"2016","journal-title":"Glob Heart"},{"key":"2024121909364697200_bib61","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1161\/01.STR.0000199613.38911.b2","article-title":"The lifetime risk of stroke: estimates from the Framingham Study","volume":"37","author":"Seshadri","year":"2006","journal-title":"Stroke"},{"key":"2024121909364697200_bib62","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/jamainternmed.2016.5451","article-title":"Lifelong gender gap in risk of incident myocardial infarction: the Troms\u00f8 study","volume":"176","author":"Albrektsen","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"2024121909364697200_bib63","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.jacc.2013.01.022","article-title":"Lifetime risk for heart failure among white and black Americans: cardiovascular lifetime risk pooling project","volume":"61","author":"Huffman","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2024121909364697200_bib64","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1681\/ASN.2012020164","article-title":"Lifetime risk of ESRD","volume":"23","author":"Turin","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2024121909364697200_bib65","doi-asserted-by":"crossref","first-page":"j2099","DOI":"10.1136\/bmj.j2099","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study","volume":"357","author":"Hippisley-Cox","year":"2017","journal-title":"Br Med J"},{"key":"2024121909364697200_bib66","article-title":"Cardiovascular risk assessment and lipid modification 2015 [updated 24 May 2023]","author":"National Institute for Health and Care Excellence (NICE)"},{"key":"2024121909364697200_bib67","article-title":"Welcome to the QRISK\u00ae3-2018 risk calculator","author":"ClinRisk"},{"key":"2024121909364697200_bib68","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0272989X12458348","article-title":"Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group\u20146","volume":"32","author":"Briggs","year":"2012","journal-title":"Med Decis Making"},{"key":"2024121909364697200_bib69","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(22)01787-1","article-title":"Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial","volume":"400","author":"Bhatt","year":"2022","journal-title":"Lancet"},{"key":"2024121909364697200_bib70","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/S0140-6736(22)00455-X","article-title":"Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial","volume":"399","author":"Mahfoud","year":"2022","journal-title":"Lancet"},{"key":"2024121909364697200_bib71","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.jacc.2022.08.802","article-title":"Cardiovascular risk reduction after renal denervation according to time in therapeutic systolic blood pressure range","volume":"80","author":"Mahfoud","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2024121909364697200_bib72","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/1479164115585298","article-title":"Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes","volume":"12","author":"Sj\u00f6str\u00f6m","year":"2015","journal-title":"Diab Vasc Dis Res"},{"key":"2024121909364697200_bib73","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1111\/dom.14451","article-title":"Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"23","author":"Tsapas","year":"2021","journal-title":"Diabetes, Obes Metab"},{"key":"2024121909364697200_bib74","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/ehjqcco\/qcac056","article-title":"Clinical event reductions in high-risk patients after renal denervation projected from the global SYMPLICITY registry","volume":"9","author":"Schmieder","year":"2023","journal-title":"Eur Heart J Qual Care Clin Outcomes"}],"container-title":["European Heart Journal - Quality of Care and Clinical Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjqcco\/advance-article-pdf\/doi\/10.1093\/ehjqcco\/qcae001\/56612750\/qcae001.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/10\/8\/698\/56612750\/qcae001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/10\/8\/698\/56612750\/qcae001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T09:37:23Z","timestamp":1734601043000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article\/10\/8\/698\/7513764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":74,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,1,9]]},"published-print":{"date-parts":[[2024,12,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjqcco\/qcae001","relation":{},"ISSN":["2058-5225","2058-1742"],"issn-type":[{"value":"2058-5225","type":"print"},{"value":"2058-1742","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,1,9]]}}}